India, June 7 -- Mold-Tek Packaging has closed the financial year 2025 with growth of around 11.8% in sales and 7% in EBITDA while profit after tax came down by around 9% due to high provision in depreciation and financial costs. Q4FY25 has been a landmark year for the company with the pharmaceutical division having crossed breakeven point and resulting in Mold-Tek making profits for the first time.

The management expects that the pharma division will continue to do extremely well in FY26 as new products are continuously being added to the pharma segment. Another positive development is the 6.8% growth in the paint segment for the current financial year , which augurs well for the company's financial position in FY26. The pharmaceutical ...